Connor, Clark & Lunn Investment Management Ltd. Avrobio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$0.75 - $1.33 $113,064 - $200,500	-150,752 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.29 - $4.04 $39,904 - $124,973	30,934 Added 25.82%	150,752 $199,000
Q4 2021 Feb 10, 2022	BUY	$3.45 - $6.05 $182,684 - $320,359	52,952 Added 79.19%	119,818 $461,000
Q3 2021 Nov 12, 2021	BUY	$5.53 - $9.28 $369,768 - $620,516	66,866 New	66,866 $373,000

Others Institutions Holding AVRO

# of Institutions

Shares Held

559K

Call Options Held

Put Options Held

Terrapin Asset Management, LLC Miami, FL

559K
Shares

$0
0.98% of portfolio

View Full List

About AVROBIO, Inc.

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

More about AVRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account